Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 9 | Vintage Vibes

Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.

Benzinga

Giro della Toscana: Isaac del Toro wins with solo attack across Monte Serra

Michael Storer outsprints Steff Cras for runner-up position from two-rider chase

Cycling News

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic maker to slash 9,000 jobs globally as competition intensifies

Novo Nordisk’s plans would result in around 11% of the pharmaceutical giant’s 78,400-strong workforce being axed.

Evening Standard

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

Euronews

Weight loss drugmaker to slash 9,000 jobs in £926 million cost cut

Novo Nordisk was at one point last year Europe's most valuable listed company

The Independent UK

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition

Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications

The Independent UK

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly

The Guardian - UK

Trump reportedly asks EU to levy 100% tariffs on India and China; Ozempic maker Novo to cut 9,000 jobs – as it happened

US president wants to up pressure on Russia to end war in Ukraine

The Guardian - UK

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

Benzinga

WHO has added GLP-1 drugs to the essential medicines list. Here’s what that means

GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too

The Independent UK

Scientists say there is no link between ‘microdosing’ weight-loss drugs and living longer

It is ‘too early’ to know whether small doses of weight-loss drugs can help you live longer, experts say

The Independent UK

After Copycat Boom, China's Drugmakers Target Global Generics

China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Euronews

The Ozempic effect: From shopping baskets to dips in Danish GDP

As GLP-1 use spreads, grocers and restaurants see lighter baskets, airlines predict fuel savings and health systems eye lower costs—while Denmark sees a clipped GDP.

Benzinga

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook

Weaker prospects for pharmaceutical giant Novo Nordisk A/S (NYSE:NVS) have prompted Denmark's economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage points from May's projection.

Benzinga

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive landscape and providing more choices for consumers.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Pregnant women face tough choices about medication use due to lack of safety data − here’s why medical research cuts will make it worse

A panel convened in July 2025 by the Food and Drug Administration sparked controversy by casting doubt about the safety of commonly used antidepressants during pregnancy. But it also raised the broader issue of how little is known about the safety of many medications used in pregnancy, considering the implications…

Benzinga

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.

Benzinga

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Kiplinger

I'm a Financial Pro: Why You Shouldn't Put All Your Eggs in the Company Stock Basket

Limit exposure to your employer's stock, sell it periodically and maintain portfolio diversification to protect your wealth from unexpected events.

The Independent UK

Voices: British Mounjaro users face a shortage and tripling prices: Think alternatives, not cold turkey

COMMENT: With Mounjaro supplies to the UK on pause, and private prescription costs set to exceed £300 from September, it’s worrying news for the half a million Brits already using weight-loss jabs. Here, doctor and epidemiologist Tim Spector assesses alternative options

Benzinga

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Bored Panda

People Are Experiencing Such Bad Ozempic Side Effects That It Might Result In $2B In Lawsuits

Ozempic reportedly faces around $2 billion in lawsuits that are about its side effects.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.